Can Poly (ADP-Ribose) Polymerase Inhibitors Palliate Paclitaxel-Induced Peripheral Neuropathy in Patients With Cancer?

Ryan A. Balko, Andrea E Wahner Hendrickson, Megan E. Grudem, Carolyn M. Klampe, Aminah Jatoi

Research output: Contribution to journalArticle

Abstract

Background: Paclitaxel-treated patients can suffer from years of peripheral neuropathy with pain, numbness, and tingling. Promising preclinical data with poly (ADP-ribose) polymerase (PARP) inhibitors led us to explore this class of agents to palliate this neuropathy. Methods: We relied on a completed trial that tested the antineoplastic effects of veliparib (NCT01012817). Data from patients who had been enrolled on NCT01012817, who previously received paclitaxel, and who had completed a validated pain assessment instrument were evaluated for improvement in their pain scores. Results: All 34 eligible patients were women, and all had a metastatic gynecological malignancy. On a 10-point scale (higher numbers indicative of worse pain), the average baseline score was 3.6 (range: 0-7). Seven patients (21%; 95% confidence interval: 9%-38%) manifested a drop in pain score (1 score lower than baseline followed by at least one consecutive value also below baseline). Of note, no patients initiated other therapy for neuropathy while on NCT01012817. Conclusion: The PARP inhibitors merit further study for chemotherapy-induced peripheral neuropathy. For patients suffering from peripheral neuropathy, these putative palliative effects might prompt earlier consideration of a PARP inhibitor as part of cancer treatment.

Original languageEnglish (US)
Pages (from-to)72-75
Number of pages4
JournalAmerican Journal of Hospice and Palliative Medicine
Volume36
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Peripheral Nervous System Diseases
Paclitaxel
Pain
Neoplasms
Hypesthesia
Pain Measurement
Antineoplastic Agents
Poly(ADP-ribose) Polymerase Inhibitors
Confidence Intervals
Drug Therapy
Therapeutics

Keywords

  • cancer
  • neuropathy
  • paclitaxel
  • pain
  • palliation
  • PARP inhibitors

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Can Poly (ADP-Ribose) Polymerase Inhibitors Palliate Paclitaxel-Induced Peripheral Neuropathy in Patients With Cancer? / Balko, Ryan A.; Wahner Hendrickson, Andrea E; Grudem, Megan E.; Klampe, Carolyn M.; Jatoi, Aminah.

In: American Journal of Hospice and Palliative Medicine, Vol. 36, No. 1, 01.01.2019, p. 72-75.

Research output: Contribution to journalArticle

@article{24699a65b1a242a8bd39d7334e2ee02c,
title = "Can Poly (ADP-Ribose) Polymerase Inhibitors Palliate Paclitaxel-Induced Peripheral Neuropathy in Patients With Cancer?",
abstract = "Background: Paclitaxel-treated patients can suffer from years of peripheral neuropathy with pain, numbness, and tingling. Promising preclinical data with poly (ADP-ribose) polymerase (PARP) inhibitors led us to explore this class of agents to palliate this neuropathy. Methods: We relied on a completed trial that tested the antineoplastic effects of veliparib (NCT01012817). Data from patients who had been enrolled on NCT01012817, who previously received paclitaxel, and who had completed a validated pain assessment instrument were evaluated for improvement in their pain scores. Results: All 34 eligible patients were women, and all had a metastatic gynecological malignancy. On a 10-point scale (higher numbers indicative of worse pain), the average baseline score was 3.6 (range: 0-7). Seven patients (21{\%}; 95{\%} confidence interval: 9{\%}-38{\%}) manifested a drop in pain score (1 score lower than baseline followed by at least one consecutive value also below baseline). Of note, no patients initiated other therapy for neuropathy while on NCT01012817. Conclusion: The PARP inhibitors merit further study for chemotherapy-induced peripheral neuropathy. For patients suffering from peripheral neuropathy, these putative palliative effects might prompt earlier consideration of a PARP inhibitor as part of cancer treatment.",
keywords = "cancer, neuropathy, paclitaxel, pain, palliation, PARP inhibitors",
author = "Balko, {Ryan A.} and {Wahner Hendrickson}, {Andrea E} and Grudem, {Megan E.} and Klampe, {Carolyn M.} and Aminah Jatoi",
year = "2019",
month = "1",
day = "1",
doi = "10.1177/1049909118786958",
language = "English (US)",
volume = "36",
pages = "72--75",
journal = "American Journal of Hospice and Palliative Medicine",
issn = "1049-9091",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Can Poly (ADP-Ribose) Polymerase Inhibitors Palliate Paclitaxel-Induced Peripheral Neuropathy in Patients With Cancer?

AU - Balko, Ryan A.

AU - Wahner Hendrickson, Andrea E

AU - Grudem, Megan E.

AU - Klampe, Carolyn M.

AU - Jatoi, Aminah

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Paclitaxel-treated patients can suffer from years of peripheral neuropathy with pain, numbness, and tingling. Promising preclinical data with poly (ADP-ribose) polymerase (PARP) inhibitors led us to explore this class of agents to palliate this neuropathy. Methods: We relied on a completed trial that tested the antineoplastic effects of veliparib (NCT01012817). Data from patients who had been enrolled on NCT01012817, who previously received paclitaxel, and who had completed a validated pain assessment instrument were evaluated for improvement in their pain scores. Results: All 34 eligible patients were women, and all had a metastatic gynecological malignancy. On a 10-point scale (higher numbers indicative of worse pain), the average baseline score was 3.6 (range: 0-7). Seven patients (21%; 95% confidence interval: 9%-38%) manifested a drop in pain score (1 score lower than baseline followed by at least one consecutive value also below baseline). Of note, no patients initiated other therapy for neuropathy while on NCT01012817. Conclusion: The PARP inhibitors merit further study for chemotherapy-induced peripheral neuropathy. For patients suffering from peripheral neuropathy, these putative palliative effects might prompt earlier consideration of a PARP inhibitor as part of cancer treatment.

AB - Background: Paclitaxel-treated patients can suffer from years of peripheral neuropathy with pain, numbness, and tingling. Promising preclinical data with poly (ADP-ribose) polymerase (PARP) inhibitors led us to explore this class of agents to palliate this neuropathy. Methods: We relied on a completed trial that tested the antineoplastic effects of veliparib (NCT01012817). Data from patients who had been enrolled on NCT01012817, who previously received paclitaxel, and who had completed a validated pain assessment instrument were evaluated for improvement in their pain scores. Results: All 34 eligible patients were women, and all had a metastatic gynecological malignancy. On a 10-point scale (higher numbers indicative of worse pain), the average baseline score was 3.6 (range: 0-7). Seven patients (21%; 95% confidence interval: 9%-38%) manifested a drop in pain score (1 score lower than baseline followed by at least one consecutive value also below baseline). Of note, no patients initiated other therapy for neuropathy while on NCT01012817. Conclusion: The PARP inhibitors merit further study for chemotherapy-induced peripheral neuropathy. For patients suffering from peripheral neuropathy, these putative palliative effects might prompt earlier consideration of a PARP inhibitor as part of cancer treatment.

KW - cancer

KW - neuropathy

KW - paclitaxel

KW - pain

KW - palliation

KW - PARP inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85049789215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049789215&partnerID=8YFLogxK

U2 - 10.1177/1049909118786958

DO - 10.1177/1049909118786958

M3 - Article

VL - 36

SP - 72

EP - 75

JO - American Journal of Hospice and Palliative Medicine

JF - American Journal of Hospice and Palliative Medicine

SN - 1049-9091

IS - 1

ER -